← 글 목록← All articles

How should a US or European claim set be adapted for Korea?

Brief summary

  • Three features typically lead to a ground for rejection if the claim set is left as it is: a multiple dependent claim that refers to another multiple dependent claim, a claim to a method of treating humans, and a program claim stated without a medium.
  • Korea charges the fee for request for examination from the first claim. For applications filed on or after 1 August 2023, the fee is KRW 166,000 plus KRW 51,000 for each claim.
  • The fee for request for examination is calculated on the number of claims at the time of the request for examination. After the request, deleting claims does not bring a refund of the fee for request for examination.

Amounts are taken from the Regulation on the Collection of Patent Fees, etc. (특허료 등의 징수규칙, “Fee Regulation”) in force from 27 February 2026. The statutory provisions and the examination guidelines were verified on 9 October 2026.

Last verified

Checklist at a glance

As of October 2026.

Feature of the original claim set Korean rule Result Form that the rules accept
A multiple dependent claim refers to another multiple dependent claim Enforcement Decree of the Patent Act, Art. 5(6) Ground for rejection for violation of Patent Act, Art. 42(8) A claim that refers to only one claim; a multiple dependent claim that refers only to claims that do not refer to two or more claims
Optional matter introduced by “preferably” or “for example”; a dual numerical range in one claim Patent Act, Art. 42(4), subparagraph 2; Examination Guidelines, Part 2, Chapter 4, 4.(3)⑤ Ground for rejection for an unclear statement An expression whose meaning is supported by the description of the invention; a generic concept and a specific concept joined by “or”
Method of surgery, treatment or diagnosis of humans Patent Act, Art. 29(1), main clause; Examination Guidelines, Part 3, Chapter 1, 5.1 Treated as an invention that is not industrially applicable A medicine or a medical device as such; a method limited to animals other than humans
Use claim in the form “a compound for treating a disease” Practice Guidelines, pharmaceutical field, 2.2.1.1 Regarded as a claim to the compound itself “A pharmaceutical composition for treating disease B comprising compound A as an active ingredient”
Computer program stated without a medium; “program product” Examination Guidelines, Part 3, Chapter 1, 4.1.8; Practice Guidelines, Chapter 10 Treated as not being an invention, or as an unclear statement A medium on which a program is recorded; a computer program stored on a medium
Element stated as a means and a function Examination Guidelines, Part 3, Chapter 2, 4.1.2(1); Part 2, Chapter 4, 3.(3)③ In principle interpreted as every product that has that function A statement for which the description of the invention has a corresponding specific configuration
Claim set with a large number of claims Fee Regulation, Art. 2(1), subparagraph 7 KRW 51,000 for each claim, for applications filed on or after 1 August 2023 The claims as amended up to the request for examination are the basis of calculation

“Examination Guidelines” means the Patent Examination Guidelines (특허·실용신안 심사기준). “Practice Guidelines” means the Examination Practice Guidelines by Technology Field (기술분야별 심사실무가이드). Both are issued by the Ministry of Intellectual Property (지식재산처, MOIP).

A multiple dependent claim that refers to another multiple dependent claim is a ground for rejection

In Korea, a claim that refers to two or more claims cannot refer to another claim that refers to two or more claims. This is the rule in Article 5(6) of the Enforcement Decree of the Patent Act (특허법 시행령). [2] The same applies to an indirect reference through an intermediate claim that refers to only one claim. [2]

The reference itself only has to be stated in the alternative (Enforcement Decree, Art. 5(5)). [2] The Examination Guidelines accept “according to any one of claims 1 to 3” as a reference in the alternative. [4] “According to claim 1, claim 2” is not a reference in the alternative. [4]

For a claim that breaks this rule, the examiner issues a notice of grounds for rejection for violation of Article 42(8) of the Patent Act (특허법). [4] Failure to meet the requirements of Article 42(8) is a ground for rejection under Article 62, subparagraph 4 of the Patent Act. [1] Article 133(1) of the Patent Act, which lists the grounds for a trial for invalidation, does not include Article 42(8). [1]

Article 5(6) of the Enforcement Decree applies only to a claim that refers to two or more claims. It does not apply to a claim that refers to only one claim (Examination Guidelines, Part 2, Chapter 4, 6.6). [4] If the claim referred to does not refer to two or more claims, either directly or indirectly, there is no violation of this paragraph. [2]

The Examination Guidelines make one exception. A claim that refers to two or more claims in order to state the invention clearly and concisely is not regarded as the prohibited form. [4] The example in the Examination Guidelines is a claim 3 in which the device used in the method of claim 2 is specified as the device of claim 1. [4]

An application that enters Korea through the PCT is subject to the same rule. An international application that designates Korea is deemed a patent application filed on its international filing date (Patent Act, Art. 199(1)). [1] The only provisions excluded by paragraph (2) of that Article are Articles 42-2, 42-3 and 54. [1]

Optionally added matter and dual numerical ranges are unclear statements

A claim to which optional matter has been added is a type of unclear statement. The Examination Guidelines, Part 2, Chapter 4, 4.(3)⑤ give “if desired” (소망에 따라), “if necessary” (필요에 따라), “in particular” (특히), “for example” (예를 들어) and “and/or” (및/또는) as examples. [4] A dual numerical limitation in one claim, such as “120-200℃, preferably 150-180℃”, is the same type. [4]

Expressions of unclear degree, such as “about” (약), “approximately” (대략) and “almost” (거의), are also in the same type. [4]

However, the Examination Guidelines make an exception. If the meaning of the expression is clearly supported by the description of the invention and there is no problem in specifying the invention, the expression is not treated as unclear. [4]

A generic concept and a specific concept can be stated in one claim in the alternative. The two matters must have a common property or function (Examination Guidelines, Part 2, Chapter 4, 4.(6)). [4] The example in the Examination Guidelines is “a method wherein X is carried out at 120-200℃ or 150-180℃”. [4]

The statutory basis is Article 42(4), subparagraph 2 of the Patent Act. [1] A violation of Article 42(4) is a ground for rejection (Art. 62, subparagraph 4) and is also a ground for a trial for invalidation (Art. 133(1), subparagraph 1). [1] This differs from a violation of Article 42(8), which is not among the grounds for a trial for invalidation. [1]

A claim that states two or more subjects for which protection is sought can also be a ground for rejection. Article 5(2) of the Enforcement Decree requires claims to be stated in a reasonable number according to the nature of the invention. [2] The Examination Guidelines give as an example one claim that states a polymer compound and a lens that uses that compound. [4] One claim that states two or more inventions in different categories is the same type. [4]

A claim to a method of treating humans is written as a product claim

The Korean Examination Guidelines do not regard a method of surgery, treatment or diagnosis of humans as an industrially applicable invention. [4] This is the standard in Part 3, Chapter 1, 5.1 of the Examination Guidelines. The statutory basis is the main clause of Article 29(1) of the Patent Act. [1] The same applies where the claim includes medical practice as only one step. [4]

A medicine as such and a medical device as such are industrially applicable inventions. [4] The Supreme Court of Korea (대법원) uses the same distinction (Supreme Court en banc Decision 2014Hu768 Decided May 21, 2015). [6] The decision held that a method invention that claims a method of treating humans as such cannot be allowed. [6] It held that an invention that adds a medical use (medicinal use) to a medicine, which is a product, can be patented as a product invention. [6] It also held that the dosage regimen and the dose can be elements of the medicine as a product. [6]

The form for stating a medical use invention is in the Practice Guidelines, pharmaceutical field, 2.2.1.1. A use invention whose use is medical is in principle stated in the form of a composition. [5] The example in the Practice Guidelines is “a pharmaceutical composition for treating disease B comprising compound A as an active ingredient”. [5]

The same section treats “compound A for treating disease B” differently. This form is regarded as a claim to compound A, not to a medical use. [5] This is a point to check when a purpose-limited product claim of a European-style claim set is carried over.

Changing a method-of-treatment claim into a composition claim is an amendment. An amendment must be made within the matters described in the original specification or drawings (Patent Act, Art. 47(2)). [1]

A method whose subject is limited to animals other than humans is treated as an industrially applicable invention. The limitation must be stated expressly in the claims. [4] The Examination Guidelines do not regard an amendment that changes “a method of treating a mammal” into “a method of treating a mammal other than a human” as an addition of new matter (Part 4, Chapter 2, 1.2 (7)). [4] This standard applies where it is not stated whether the subject is a human or an animal, and it is obvious that the invention is not directed only to a specific animal. [4]

Some methods are treated as industrially applicable inventions even where the subject is a human. A method of operating a medical device and a measuring method that uses a medical device are such methods. However, cases such as those that include substantive medical practice are excluded (Examination Guidelines, 5.1 (2)②). [4] A diagnosis-related method that does not include clinical judgment is also such a method (5.1 (2)④). [4]

A program claim states a medium

The Korean Examination Guidelines do not regard a computer program per se as an invention (Part 3, Chapter 1, 4.1.8). [4] Where information processing is concretely realised by using hardware, four forms qualify as an invention. They are an apparatus, the method of operating it, a computer-readable medium on which a program is recorded, and a computer program stored on a medium. [4]

The form “a computer program stored on a medium” applies to applications filed on or after 1 July 2014. [4][5]

Chapter 10 of the Practice Guidelines of the Ministry of Intellectual Property gives examples for each form. “A computer program stored on a medium to cause a computer to execute step A, step B and step C” is an example that is allowed. [5] A computer program that is not stored on a medium is not allowed, because it claims the program as such. [5]

If the claim ends in “program product” (프로그램 제품, 프로그램 프로덕트) or “program output” (프로그램 산출물), the invention is regarded as not clear. [5] If the claim ends in “program signal” (프로그램 신호), the category is regarded as not clear. [5]

Even if the claim ends in “computer-readable recording medium”, the description of the invention is read together with it. In some cases the recording medium, according to the description of the invention, also covers a transmission medium. The Practice Guidelines regard this case as an unclear statement (Chapter 10, 1.2.3 (2)). [5] The Practice Guidelines are not a statute or regulation. They are a standard that examiners follow.

An element stated as a means and a function is interpreted as every product that has that function

Korea allows a function to be stated in a claim. Article 42(6) of the Patent Act provides that the claims state the structure, method, function, material or combination of these. [1]

The Examination Guidelines in principle interpret a statement that specifies a product by its function as every product that has that function (Part 3, Chapter 2, 4.1.2(1)). [4] This standard is stated as a principle for specifying the invention when novelty is assessed. [4]

There are two exceptions. One is where the description of the invention expressly defines the statement as having a specific meaning. [4] The other is where it is difficult to interpret the statement as every such product in light of the common general technical knowledge at the time of filing. [4]

US law, 35 U.S.C. 112(f), provides differently. An element stated as a means and a function is to be interpreted as the corresponding structure described in the specification and its equivalents. [8]

The description requirements are examined as well. A matter stated as a “means” or a “step” must have a corresponding specific configuration in the description of the invention. The Examination Guidelines give the case where there is no such configuration as a type of claim that is not supported (Part 2, Chapter 4, 3.(3)③). [4] A functional expression is not allowed unless the configuration of the invention is clear as a whole (same Chapter, 4.(7)). [4]

Every claim costs money, from the first claim

The Korean fee for request for examination is KRW 166,000 plus KRW 51,000 for each claim (Fee Regulation, Art. 2(1), subparagraph 7). [3] The provision has no number of claims that are free of charge. [3]

This amount applies to patent applications filed on or after 1 August 2023. Applications filed before that date follow the previous provisions (Ordinance of the Ministry of Trade, Industry and Energy No. 517, in force from 1 August 2023, Addenda Art. 3(2)). [3] The previous amount is KRW 143,000 plus KRW 44,000 for each claim. [3]

For an international patent application, the international filing date decides. This is because Article 199(1) of the Patent Act deems an international patent application to be a patent application filed on its international filing date. [1]

Claims are counted one by one, with no distinction between independent claims and dependent claims. A claim that refers to two or more claims is also counted as one claim. [4]

The basis of calculation is the claims at the time of the request for examination (Examination Guidelines, Part 1, Chapter 7). [4] If the number of claims has changed by amendment before the request for examination, the fee is calculated on the claims as last amended. [4] If a written amendment and the request for examination are filed together, the fee is calculated on the claims at that time. [4]

If claims are added by amendment after the request for examination, KRW 51,000 is paid for each added claim (Fee Regulation, Art. 2(1), subparagraph 9). [3] This amount applies to applications filed on or after 1 May 2024. For earlier applications it is KRW 44,000 for each claim (Ordinance of the Ministry of Trade, Industry and Energy No. 556, in force from 1 May 2024, Addenda Art. 3). [3] Here too, the international filing date decides for an international patent application. [1]

Added claims are not set off against deleted claims. In the example in the Examination Guidelines, where 1 claim is deleted and 5 claims are newly added, the fee for 5 claims is paid. [4] If several amendments are filed within one period for submission of a written argument, only the claims added by the last amendment in that period are counted (subparagraph 9). [3]

An amendment filed with a request for re-examination is excluded from subparagraph 9. [3] Re-examination has its own fee for request for re-examination. It is KRW 100,000 plus KRW 10,000 for each claim (Fee Regulation, Art. 2(1), subparagraph 7-2). [3]

If claims are deleted after the request for examination, the fee for request for examination already paid is not refunded. [4]

The time for adapting the claims is set by the amendment provisions

The applicant can amend the specification until a certified copy of the decision to grant is served (Patent Act, Art. 47(1)). [1] After a notice of grounds for rejection has been received, amendment is possible only at set times, such as the period for submission of a written argument. [1] An amendment must be made within the matters described in the original specification or drawings (Art. 47(2)). [1]

For an international patent application filed in a foreign language, this scope is read differently. The basis is the description of the invention, the claims or the drawings submitted by the international filing date (Patent Act, Art. 208(3)). [1] The amendment must also stay within the final Korean translation or the drawings submitted by the international filing date (Art. 208(4)). [1] The Examination Guidelines apply this standard to applications filed on or after 1 January 2015 (Part 5, Chapter 3, 4.(4)). [4]

Amendment of the claims is narrower after a notice of grounds for rejection that addresses grounds caused by an amendment, and when re-examination is requested. It is limited to narrowing the claims by limiting or deleting a claim or adding to a claim, correction of clerical errors, clarification of an ambiguous description, and the like (Art. 47(3)). [1]

International patent applications have further requirements. An applicant who filed in a foreign language must submit a Korean translation of the claims submitted by the international filing date (Patent Act, Art. 201(1), subparagraph 1). [1] The applicant can replace it with a translation of the claims as amended under Article 19 of the Patent Cooperation Treaty (Art. 201(2)). [1]

An international patent application can be amended only when three requirements are all met (Patent Act, Art. 208(1)). [1] The official fees must be paid, the Korean translation must be submitted, and the reference date must have passed. [1] An international patent application filed in Korean has no translation requirement (Art. 208(1), subparagraph 2, proviso). [1]

The reference date is the expiration date of the period for submitting domestic documents. If the applicant requests examination within that period, the date of the request is the reference date (Art. 201(5)). [1] In that case, amendment is possible only after the time at which examination was requested (Art. 208(1), subparagraph 3). [1] The period for submitting domestic documents is 2 years and 7 months from the priority date (Art. 201(1)). [1] If the period for submitting the translation has been extended, the extended period is used (Art. 201(3)). [1]

Amendments made in the international phase are not subject to these three requirements (Art. 208(1)). [1] It is enough to submit, by the reference date, a Korean translation of the written amendment under Article 19 or Article 34 of the Patent Cooperation Treaty. The application is then deemed amended according to that translation (Art. 204(2), Art. 205(2)). [1] If the translation is not submitted by the reference date, the written amendment is deemed not to have been submitted (Art. 204(4), Art. 205(3)). [1]

Examination can be requested within three years from the filing date of the patent application (Patent Act, Art. 59(2)). [1] The three-year period applies to applications filed on or after 1 March 2017 (Addenda to Act No. 14035, Art. 19). [1] The applicant of an international patent application can request examination only after submitting the Korean translation and paying the official fees (Art. 210, subparagraph 1). [1]

A patent application in a foreign language can be amended only if the Korean translation has been submitted (Art. 47(5)). [1] A patent application in a foreign language is a patent application filed in Korea with the specification written in a foreign language (Art. 42-3(2)). [1] Article 42-3 does not apply to international patent applications (Art. 199(2)). [1]

Example

This is an assumed case. The application was filed on or after 1 May 2024 and there is no fee reduction.

The fee for request for examination by number of claims is as follows. [3]

Number of claims Calculation Fee for request for examination
25 claims KRW 166,000 + 25 × KRW 51,000 KRW 1,441,000
20 claims KRW 166,000 + 20 × KRW 51,000 KRW 1,186,000
18 claims KRW 166,000 + 18 × KRW 51,000 KRW 1,084,000

If a 25-claim set is amended down to 18 claims by the time of the request for examination, the fee falls by KRW 357,000. [3][4]

The following is an example of correcting the references. Assume that the original claim set is as follows.

  • Claim 3: according to claim 1 or claim 2, …
  • Claim 4: according to any one of claims 1 to 3, …

Claim 4 refers to two or more claims and also refers to claim 3, which is a multiple dependent claim. This violates Article 5(6) of the Enforcement Decree. [2]

  • Correction 1: reduce the reference in claim 4 to “claim 1 or claim 2”. The number of claims stays the same.
  • Correction 2: reduce the reference in claim 4 to “claim 1 or claim 2”. In addition, add a new claim 5 that refers only to claim 3. There is one more claim, which costs a further KRW 51,000. [3]

How Korea differs

The US rule (37 CFR 1.75(c)) also provides that a multiple dependent claim cannot serve as a basis for another multiple dependent claim. [7] The difference is in the fees. The United States counts a multiple dependent claim as the number of claims to which it directly refers (37 CFR 1.75(c)). [7] An application that contains a multiple dependent claim pays a separate USD 925 per application (37 CFR 1.16(j), amount without reduction). [7] Korea counts a multiple dependent claim as one claim. [4]

The United States charges fees for the excess when there are more than 20 claims or more than 3 independent claims (37 CFR 1.16(h) and (i)). [7] The European Patent Office charges claims fees from the 16th claim (EPC Rule 45(1)). [9] Korea charges from the first claim. [3]

The EPO Guidelines for Examination state that a dependent claim can refer to one or more dependent claims (Guidelines F-IV 3.4). [10] That section and EPC Rule 43(4) contain no sentence that prevents a multiple dependent claim from referring to another multiple dependent claim. [9][10] The references in a European-style claim set therefore have to be reviewed again when the set enters Korea.

EPC Rule 43(2) allows more than one independent claim in the same category only in specified cases. [9] Article 5 of the Korean Enforcement Decree has no such paragraph. [2] The Korean standards are the group of inventions requirement of Article 45 of the Patent Act and the reasonable number of claims under Article 5(2) of the Enforcement Decree. [1][2]

EPC Rule 43(1) requires claims, where appropriate, to be divided into a preamble and a characterising portion. [9] Article 5 of the Korean Enforcement Decree has no such paragraph either. [2]

Europe also does not grant patents for methods of treatment (EPC Article 53(c)). [9] This exclusion does not apply to products, such as substances or compositions, for use in those methods (Article 53(c), latter part). [9] A known substance is not excluded from patentability if that use is not in the prior art (Article 54(4) and (5)). [9] The Korean Practice Guidelines require a medical use invention to be stated in principle in the form of a composition. [5]

The Manual of Patent Examining Procedure (MPEP) of the USPTO has a section on particular treatment or prophylaxis (MPEP 2106.04(d)(2)). [8] It states that a claim that recites a judicial exception is eligible at Step 2A if it applies the exception to a particular treatment or prophylaxis. [8] In Korea, a method of treating humans is not treated as an industrially applicable invention. [4]

What applicants should do

  • In general, we suggest reviewing the claim set before it is sent for translation. If the references, the method-of-treatment claims and the program claims are marked first, the written amendment can be prepared at one time.
  • We suggest settling the number of claims before requesting examination. After the request, deleting claims does not bring the official fee back, and each added claim is charged.
  • For an international patent application, we suggest deciding the order of the request for examination and the amendment first. If examination is requested within the period for submitting domestic documents, amendment is possible only after the time of the request.
  • We suggest moving optional matter introduced by “preferably” into dependent claims.
  • In a US-style claim set, dependent claims that were written out so that each refers to only one claim are worth considering for merging into multiple dependent claims. The reason is that Korea counts a multiple dependent claim as one claim. Check at the same time that no other multiple dependent claim refers to the merged claim.
  • Before changing a method-of-treatment claim into a product claim, we suggest reading the specification first. It must contain sentences that support the composition, the use and the dosage regimen.
  • For an independent claim stated as a means and a function, we suggest keeping dependent claims that state the corresponding configuration. They give a position to fall back to when prior art is cited.
  • The claim structure of an individual case should be confirmed with a Korean agent.

FAQ

Can the claims be changed in the translation filed at national phase entry?

The Korean translation required by the statute is a translation of the claims submitted by the international filing date (Patent Act, Art. 201(1), subparagraph 1). [1] It can be replaced by a translation of the claims as amended under Article 19 of the Patent Cooperation Treaty (Art. 201(2)). [1] The procedure that the statute provides for changing the claims in the national phase is amendment. Payment of the official fees, submission of the translation and passing of the reference date are required (Art. 208(1)). [1]

Can a dependent claim that reads “according to any one of claims 1 to 5” be used as it is?

The wording itself is accepted as a reference in the alternative. [4] However, if any of claims 1 to 5 referred to is a multiple dependent claim, the claim violates Article 5(6) of the Enforcement Decree. [2]

How much does the cost rise if a multiple dependent claim is split into several claims?

For applications filed on or after 1 August 2023, KRW 51,000 is added to the fee for request for examination for each claim at the time of the request for examination. [3] For applications filed on or after 1 May 2024, a claim added by amendment after the request for examination also costs KRW 51,000. [3] For applications filed before that date, each added claim costs KRW 44,000. [3]

Can the claims be corrected after a notice of grounds for rejection?

Amendment is possible within the period for submission of a written argument (Patent Act, Art. 47(1)). [1] However, after a notice that addresses grounds for rejection caused by an amendment, amendment of the claims is limited to narrowing and the like (Art. 47(3)). [1]

How DEFINE IP Law Firm handles this

DEFINE IP Law Firm checks a claim set received from abroad against the Korean rules on the manner of stating the claims before the set is sent for translation. DEFINE IP Law Firm manages the number of claims as a cost item during prosecution. We confirm with the applicant which claims to keep at two points: before the request for examination and before payment of the registration fee. Subject matter of claims that are removed is recorded separately as a candidate for a divisional application. For questions about the claim structure of Korean applications, please write to contact@defineip.kr.

Sources

  1. Patent Act (특허법), Act No. 21134, in force from 11 November 2025. Articles 29, 42, 42-3, 45, 47, 59, 62, 133, 199, 201, 204, 205, 208 and 210, Addenda (Act No. 14035, 29 February 2016) Art. 19. https://www.law.go.kr/법령/특허법 (verified 9 October 2026)
  2. Enforcement Decree of the Patent Act (특허법 시행령), Presidential Decree No. 35809, in force from 1 October 2025. Article 5. https://www.law.go.kr/법령/특허법시행령 (verified 9 October 2026)
  3. Ministry of Intellectual Property (지식재산처), Regulation on the Collection of Patent Fees, etc. (특허료 등의 징수규칙), Prime Ministerial Decree No. 2098, in force from 27 February 2026. Article 2(1), subparagraphs 7, 7-2 and 9, Addenda (Ordinance of the Ministry of Trade, Industry and Energy No. 517, in force from 1 August 2023) Art. 3(2), Addenda (Ordinance of the Ministry of Trade, Industry and Energy No. 556, in force from 1 May 2024) Art. 3. Previous amounts are from the version in force from 4 February 2023 (Ordinance of the Ministry of Trade, Industry and Energy No. 499) and the version in force from 1 August 2023 (Ordinance of the Ministry of Trade, Industry and Energy No. 517). https://www.law.go.kr/법령/특허료등의징수규칙 (verified 9 October 2026)
  4. Ministry of Intellectual Property (지식재산처), Patent Examination Guidelines (특허·실용신안 심사기준), MOIP Established Rule No. 7, in force from 13 March 2026. Part 1, Chapter 7; Part 2, Chapter 4, 3., 4. and 6.; Part 3, Chapter 1, 4.1.8 and 5.1; Part 3, Chapter 2, 4.1.2; Part 4, Chapter 2, 1.2; Part 5, Chapter 3, 4. https://www.law.go.kr/행정규칙/특허·실용신안심사기준 (verified 9 October 2026)
  5. Ministry of Intellectual Property (지식재산처), Examination Practice Guidelines by Technology Field (기술분야별 심사실무가이드), March 2026 edition. Other fields, Chapter 10, Computer-related Invention, 1.2.1, 1.2.2 and 1.2.3. Part 5, pharmaceutical field, 2.2.1.1. https://www.kipo.go.kr/ko/kpoContentView.do?menuCd=SCD0200147 (verified 9 October 2026)
  6. Supreme Court of Korea (대법원), Supreme Court en banc Decision 2014Hu768 Decided May 21, 2015 (2014후768). https://www.law.go.kr/판례/(2014후768) (verified 9 October 2026)
  7. United States, 37 CFR 1.75(c), 1.16(h), (i) and (j), eCFR as of 6 October 2026. https://www.ecfr.gov/current/title-37/section-1.75 , https://www.ecfr.gov/current/title-37/section-1.16 (verified 9 October 2026)
  8. USPTO, 35 U.S.C. 112(f) (MPEP Appendix L) and MPEP 2106.04(d)(2), page last modified 9 March 2026. https://www.uspto.gov/web/offices/pac/mpep/mpep-9015-appx-l.html , https://www.uspto.gov/web/offices/pac/mpep/s2106.html (verified 9 October 2026)
  9. EPO, European Patent Convention Rule 43, Rule 45, Article 53, Article 54. https://www.epo.org/en/legal/epc/2020/r43.html (verified 9 October 2026)
  10. EPO, Guidelines for Examination, Part F, Chapter IV, 3.4 (2026 edition). https://www.epo.org/en/legal/guidelines-epc/2026/f_iv_3_4.html (verified 9 October 2026)